Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC

John V. Heymach, David Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck

Cancer Res (2023) 83 (8_Supplement): CT005.

https://doi.org/10.1158/1538-7445.AM2023-CT005

Published: 29 May 2023

View article titled, Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC

Journal Articles

Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial

Cancer Res (2022) 82 (12_Supplement): CT012.

https://doi.org/10.1158/1538-7445.AM2022-CT012

Published: 15 June 2022

View article titled, Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial

Journal Articles

Abstract 3255: Probing and overcoming KRAS^G12C inhibitor resistance by combination with a pan-KRAS SOS1 inhibitor

Marco H. Hofmann, Sabine Jurado, Daniel Gerlach, Takamasa Koga, Francesca Trapani, Michael Gmachl, Donat Alpar, Simone Lieb, Astrid Jeschko, Tetsuya Mitsudomi, Norbert Kraut, Mark P. Petronczki

Cancer Res (2022) 82 (12_Supplement): 3255.

https://doi.org/10.1158/1538-7445.AM2022-3255

Published: 15 June 2022

View article titled, Abstract 3255: Probing and overcoming KRASG12C inhibitor resistance by combination with a pan-KRAS SOS1 inhibitor

Journal Articles

Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial

Cancer Res (2021) 81 (13_Supplement): CT003.

https://doi.org/10.1158/1538-7445.AM2021-CT003

Published: 01 July 2021

View article titled, Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial

Journal Articles

Abstract 2052: Tumor mutation burden as a biomarker of relapse free survival of non-squamous non-small cell lung cancer treated with PEM/CDDP in adjuvant setting (the JIPANG-TR)

Masahiro Tsuboi, Kazuto Nishio, Kazuko Sakai, Hirotsugu Kenmotsu, Takeharu Yamanaka, Toshiaki Takahashi, Koichi Goto, Haruko Daga, Norihiko Ikeda, Takashi Seto, Shinichi Toyooka, Hiroshi Date, Tetsuya Mitsudomi, Isamu Okamoto, Hideo Saka, Hiroaki Okamoto, Yuichi Takiguchi, Nobuyuki Yamamoto

Cancer Res (2020) 80 (16_Supplement): 2052.

https://doi.org/10.1158/1538-7445.AM2020-2052

Published: 15 August 2020

View article titled, Abstract 2052: Tumor mutation burden as a biomarker of relapse free survival of non-squamous non-small cell lung cancer treated with PEM/CDDP in adjuvant setting (the JIPANG-TR)

Journal Articles

Abstract 2200: Potent in vitro activity of Tarloxotinib for EGFR C797S and other mutations refractory to current EGFR tyrosine kinase inhibitors

Kenichi Suda, Masaya Nishino, Takamasa Koga, Toshio Fujino, Yoshihisa Kobayashi, Tetsuya Mitsudomi, Avanish Vellanki, Vijaya G. Tirunagaru

Cancer Res (2019) 79 (13_Supplement): 2200.

https://doi.org/10.1158/1538-7445.AM2019-2200

Published: 01 July 2019

View article titled, Abstract 2200: Potent in vitro activity of Tarloxotinib for EGFR C797S and other mutations refractory to current EGFR tyrosine kinase inhibitors

Journal Articles

Abstract 1668: A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing

Masayuki Takeda, Kazuko Sakai, Shigeki Shimizu, Takayuki Takahama, Takeshi Yoshida, Satomi Watanabe, Tsutomu Iwasa, Kimio Yonesaka, Shinichiro Suzuki, Hidetoshi Hayashi, Hisato Kawakami, Yoshikane Nonagase, Kaoru Tanaka, Junji Tsurutani, Kazumasa Saigo, Akihiko Ito, Tetsuya Mitsudomi, Kazuhiko Nakagawa, Kazuto Nishio

Cancer Res (2019) 79 (13_Supplement): 1668.

https://doi.org/10.1158/1538-7445.AM2019-1668

Published: 01 July 2019

View article titled, Abstract 1668: A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing

Journal Articles

Abstract 4583: Heterogeneity in immune biomarker expression: Detailed analysis of a case with SCLC transformation after EGFR-TKI treatment

Kenichi Suda, Isao Murakami, Hui Yu, Jihye Kim, Kim Ellison, Christopher J. Rivard, Tetsuya Mitsudomi, Fred R. Hirsch

Cancer Res (2017) 77 (13_Supplement): 4583.

https://doi.org/10.1158/1538-7445.AM2017-4583

Published: 01 July 2017

View article titled, Abstract 4583: Heterogeneity in immune biomarker expression: Detailed analysis of a case with SCLC transformation after EGFR-TKI treatment

Journal Articles

Heterogeneity in Tumors and Resistance to EGFR TKI Therapy—Letter

Kenichi Suda, Christopher J. Rivard, Tetsuya Mitsudomi, Fred R. Hirsch

Cancer Res (2016) 76 (10): 3109–3110.

https://doi.org/10.1158/0008-5472.CAN-15-2916

Published: 12 May 2016

View article titled, Heterogeneity in Tumors and Resistance to EGFR TKI Therapy—Letter

Journal Articles

Abstract 4468: Cripto-1 elicits innate resistance to EGFR inhibitors in non-small cell lung cancer harboring EGFR-sensitizing mutations.

Kang-Seo Park, Giaccone Giuseppe, Yisong Wang, Trung Pham, Yongwha Moon, Ji Luo, Liam Changwoo Lee, Tetsuya Mitsudomi, Isamu Okamoto, Yasushi Yatabe, Tony Mok, Mark Raffeld, Liqiang Xi, David S. Salomon, Caterina Bianco

Cancer Res (2013) 73 (8_Supplement): 4468.

https://doi.org/10.1158/1538-7445.AM2013-4468

Published: 15 April 2013

View article titled, Abstract 4468: Cripto-1 elicits innate resistance to EGFR inhibitors in non-small cell lung cancer harboring EGFR-sensitizing mutations.

Journal Articles

Abstract 2101A: CNX-2006, a novel irreversible epidermal growth factor receptor (EGFR) inhibitor, selectively inhibits EGFR T790M and fails to induce T790M-mediated resistance in vitro.

Kadoaki Ohashi, Kenichi Suda, Jing Sun, Yumei Pan, Annette O. Walter, Alex Dubrovskiy, Robert Tjin, Tetsuya Mitsudomi, William Pao

Cancer Res (2013) 73 (8_Supplement): 2101A.

https://doi.org/10.1158/1538-7445.AM2013-2101A

Published: 15 April 2013

View article titled, Abstract 2101A: CNX-2006, a novel irreversible epidermal growth factor receptor (EGFR) inhibitor, selectively inhibits EGFR T790M and fails to induce T790M-mediated resistance in vitro.

Journal Articles

Abstract 1791: CO-1686, a novel mutant-selective EGFR inhibitor, overcomes T790M mediated resistance in Non-Small Cell Lung Cancer (NSCLC)

Annette O. Walter, Robert Tjin, Henry Haringsma, Kevin Lin, Alex Dubrovskiy, Kwangho Lee, Thia St. Martin, Russell Karp, Zhendong Zhu, Deqiang Nu, Mariana Nacht, Kenichi Suda, Tetsuya Mitsudomi, Russell C. Petter, William F. Westlin, Juswinder Singh, Mitch Raponi, Andrew Allen

Cancer Res (2012) 72 (8_Supplement): 1791.

https://doi.org/10.1158/1538-7445.AM2012-1791

Published: 15 April 2012

View article titled, Abstract 1791: CO-1686, a novel mutant-selective EGFR inhibitor, overcomes T790M mediated resistance in Non-Small Cell Lung Cancer (NSCLC)

Journal Articles

Abstract 1209: Detection of EGFR T790M mutation in non-small-cell lung cancer patients using colony hybridization assay

Yoshihiko Fujita, Kenichi Suda, Hideharu Kimura, Kazuko Matsumoto, Tokuzo Arao, Tomoyuki Nagai, Hidetoshi Hayashi, Kazuyuki Furuta, Hiroaki Kato, Nagahiro Saijo, Yasushi Yatabe, Tetsuya Mitsudomi, kazuto Nishio

Cancer Res (2012) 72 (8_Supplement): 1209.

https://doi.org/10.1158/1538-7445.AM2012-1209

Published: 15 April 2012

View article titled, Abstract 1209: Detection of EGFR T790M mutation in non-small-cell lung cancer patients using colony hybridization assay

Journal Articles

Abstract 7: Knockdown of EGFR to investigate its therapeutic potential for treatment of non-small cell lung cancers

Junichi Soh, Kazuhiko Shien, Tsuyoshi Ueno, Kazunori Tsukuda, Kenichi Suda, Takafumi Kubo, Masashi Furukawa, Takayuki Muraoka, Yuho Maki, Norimitsu Tanaka, Hiromasa Yamamoto, Katsuyuki Kiura, Tetsuya Mitsudomi, Shinichi Toyooka, Shinichiro Miyoshi

Cancer Res (2012) 72 (8_Supplement): 7.

https://doi.org/10.1158/1538-7445.AM2012-7

Published: 15 April 2012

View article titled, Abstract 7: Knockdown of EGFR to investigate its therapeutic potential for treatment of non-small cell lung cancers

Journal Articles

Abstract 718: Acquired epithelial-mesenchymal transition like feature in an EGFR-mutant lung cancer cell line with acquired resistance to erlotinib

Kenichi Suda, Kenji Tomizawa, Hirotaka Osada, Yoshitaka Sekido, Yasushi Yatabe, Tetsuya Mitsudomi

Cancer Res (2011) 71 (8_Supplement): 718.

https://doi.org/10.1158/1538-7445.AM2011-718

Published: 15 April 2011

View article titled, Abstract 718: Acquired epithelial-mesenchymal transition like feature in an EGFR-mutant lung cancer cell line with acquired resistance to erlotinib

Journal Articles

Novel Metastasis-Related Gene CIM Functions in the Regulation of Multiple Cellular Stress–Response Pathways

Kiyoshi Yanagisawa, Hiroyuki Konishi, Chinatsu Arima, Shuta Tomida, Toshiyuki Takeuchi, Yukako Shimada, Yasushi Yatabe, Tetsuya Mitsudomi, Hirotaka Osada, Takashi Takahashi

Cancer Res (2010) 70 (23): 9949–9958.

https://doi.org/10.1158/0008-5472.CAN-10-1055

Published: 06 December 2010

View article titled, Novel Metastasis-Related Gene CIM Functions in the Regulation of Multiple Cellular Stress–Response Pathways

Includes: Supplementary data

Journal Articles

Relationship of Deregulated Signaling Converging onto mTOR with Prognosis and Classification of Lung Adenocarcinoma Shown by Two Independent In silico Analyses

Hiromichi Ebi, Shuta Tomida, Toshiyuki Takeuchi, Chinatsu Arima, Takahiko Sato, Tetsuya Mitsudomi, Yasushi Yatabe, Hirotaka Osada, Takashi Takahashi

Cancer Res (2009) 69 (9): 4027–4035.

https://doi.org/10.1158/0008-5472.CAN-08-3403

Published: 30 April 2009

View article titled, Relationship of Deregulated Signaling Converging onto mTOR with Prognosis and Classification of Lung Adenocarcinoma Shown by Two Independent In silico Analyses

Includes: Supplementary data

Journal Articles

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations

Seiji Yano, Wei Wang, Qi Li, Kunio Matsumoto, Haruko Sakurama, Takahiro Nakamura, Hirokazu Ogino, Soji Kakiuchi, Masaki Hanibuchi, Yasuhiko Nishioka, Hisanori Uehara, Tetsuya Mitsudomi, Yasushi Yatabe, Toshikazu Nakamura, Saburo Sone

Cancer Res (2008) 68 (22): 9479–9487.

https://doi.org/10.1158/0008-5472.CAN-08-1643

Published: 14 November 2008

View article titled, Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations

Includes: Supplementary data

Journal Articles

Epidermal Growth Factor Receptor Gene Amplification Is Acquired in Association with Tumor Progression of EGFR-Mutated Lung Cancer

Yasushi Yatabe, Takashi Takahashi, Tetsuya Mitsudomi

Cancer Res (2008) 68 (7): 2106–2111.

https://doi.org/10.1158/0008-5472.CAN-07-5211

Published: 01 April 2008

View article titled, Epidermal Growth Factor Receptor Gene Amplification Is Acquired in Association with Tumor Progression of EGFR-Mutated Lung Cancer

Journal Articles

Lineage-Specific Dependency of Lung Adenocarcinomas on the Lung Development Regulator TTF-1

Hisaaki Tanaka, Kiyoshi Yanagisawa, Keiko Shinjo, Ayumu Taguchi, Ken Maeno, Shuta Tomida, Yukako Shimada, Hirotaka Osada, Takayuki Kosaka, Hideo Matsubara, Tetsuya Mitsudomi, Yoshitaka Sekido, Mitsune Tanimoto, Yasushi Yatabe, Takashi Takahashi

Cancer Res (2007) 67 (13): 6007–6011.

https://doi.org/10.1158/0008-5472.CAN-06-4774

Published: 06 July 2007

View article titled, Lineage-Specific Dependency of Lung Adenocarcinomas on the Lung Development Regulator TTF-1

Includes: Supplementary data

NARROW

Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC

Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial

Abstract 3255: Probing and overcoming KRAS^G12C inhibitor resistance by combination with a pan-KRAS SOS1 inhibitor

Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial

Abstract 2052: Tumor mutation burden as a biomarker of relapse free survival of non-squamous non-small cell lung cancer treated with PEM/CDDP in adjuvant setting (the JIPANG-TR)

Abstract 2200: Potent in vitro activity of Tarloxotinib for EGFR C797S and other mutations refractory to current EGFR tyrosine kinase inhibitors

Abstract 1668: A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing

Abstract 4583: Heterogeneity in immune biomarker expression: Detailed analysis of a case with SCLC transformation after EGFR-TKI treatment

Heterogeneity in Tumors and Resistance to EGFR TKI Therapy—Letter

Abstract 4468: Cripto-1 elicits innate resistance to EGFR inhibitors in non-small cell lung cancer harboring EGFR-sensitizing mutations.

Abstract 2101A: CNX-2006, a novel irreversible epidermal growth factor receptor (EGFR) inhibitor, selectively inhibits EGFR T790M and fails to induce T790M-mediated resistance in vitro.

Abstract 1791: CO-1686, a novel mutant-selective EGFR inhibitor, overcomes T790M mediated resistance in Non-Small Cell Lung Cancer (NSCLC)

Abstract 1209: Detection of EGFR T790M mutation in non-small-cell lung cancer patients using colony hybridization assay

Abstract 7: Knockdown of EGFR to investigate its therapeutic potential for treatment of non-small cell lung cancers

Abstract 718: Acquired epithelial-mesenchymal transition like feature in an EGFR-mutant lung cancer cell line with acquired resistance to erlotinib

Novel Metastasis-Related Gene CIM Functions in the Regulation of Multiple Cellular Stress–Response Pathways

Relationship of Deregulated Signaling Converging onto mTOR with Prognosis and Classification of Lung Adenocarcinoma Shown by Two Independent In silico Analyses

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations

Epidermal Growth Factor Receptor Gene Amplification Is Acquired in Association with Tumor Progression of EGFR-Mutated Lung Cancer

Lineage-Specific Dependency of Lung Adenocarcinomas on the Lung Development Regulator TTF-1

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only